Paracetamol IV Market Size, Share & Trends Analysis Report By Application (Surgical, Non-surgical), By Indication (Pyrexia, Pain), By End-use (Hospitals, Clinics), By Region (APAC, Europe)- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2022-2030

According to Nova one advisor, the global Paracetamol IV market size was estimated at USD 980.24 million in 2022 and is projected to hit around USD 1.80 billion by 2030, growing at a CAGR of 3.17% during the forecast period 2022 to 2030.

Key Takeaways:

  • Based on application, the pyrexia segment is estimated to register the fastest CAGR from 2022 to 2030
  • The growth of the segment is attributed to the rapid action & effectiveness of paracetamol being administered intravenously
  • The surgical application segment held the largest revenue share in 2021 due to the increased usage of paracetamol IV for the treatment of post-operative pain and rapid relief from fever
  • North America dominated the global industry in 2021 owing to high product usage for reducing the dependence of the economy on opioids for the management of pain
  • Companies are focusing on geographical expansion by adopting strategies, such as collaborations, partnerships, new product launches, and strategic initiatives to maintain a competitive position in the industry

The market is driven by the increasing use of paracetamol IV in reducing pain and relieving fever in post-surgical procedures. Paracetamol when given intravenously acts as an effective treatment option in relieving pain and gives rapid relief. Moreover, the use of intravenous paracetamol in combination with NSAIDs and narcotics has been gaining popularity and acceptance, which further propels the growth of the industry. The COVID-19 pandemic had a significant impact on the industry. In mid-March, the American College of Surgeons (ACS) and other significant surgical specialty societies published guidelines for triage of elective surgical procedures by surgical specialty & advised minimizing, delaying, or canceling elective surgical procedures.

The rising prevalence of chronic disorders that requires pain management is expected to facilitate the growth of the industry during the forecast period. The enhanced usage of acetaminophen to reduce the dependence on opioids for pain management is projected to accelerate the growth in demand for paracetamol IV. The IV paracetamol is a stable acetaminophen form and is intended for mild to moderate pain management. It is used over other NSAIDs to treat patients with a history of peptic ulcers and asthma, as it lacks interference with the function of platelets.

Rising cases of patients reporting postoperative pain are expected to propel the demand for drugs and products with fewer side effects. As per the article published in the International Journal of Surgery, in March 2022, 77% - 83% of patients in the U.S., 80% of patients in Thailand, 76% of patients in Sweden, and 29.5% of patients in Germany reported severe to moderate postoperative pain. The IV paracetamol is intended for usage in the treatment of acute postoperative pain and during the surgeries, such as orthopedic, dental, and gynecological. A rise in the number of surgeries performed and patients experiencing post-operative pain is expected to create a high product demand in the years to come. However, the availability of multiple generic products is expected to hinder the industry during the forecast period.

For instance, in December 2020, Sandoz International GmbH launched a generic acetaminophen injection in the U.S. The product will be available in 10 mg/mL concentration, in a 100 mL vial for the treatment of mild to moderate in conjunction with opioid analgesics for pediatric patients. Key players operating in the global industry are following various strategic initiatives for business expansion and to gain a competitive edge over others. For instance, in December 2021, Leucadia Pharmaceuticals launched and announced the availability of a generic acetaminophen injection, which is an FDA-approved generic that corresponds to the acetaminophen injection manufactured by Mallinckrodt Pharmaceuticals.

Report Scope of the Paracetamol IV Market

Report Coverage


Market Size

USD 1.80 Billion by 2030

Growth Rate

CAGR of 3.17% from 2022 to 2030

Largest Market

Asia Pacific

Fastest Growing Market

North America

Base Year


Forecast Period

2022 to 2030

Segments Covered

Indication, application, end-use and Region,

Companies Mentioned

Mallinckrodt (Mallinckrodt Pharmaceuticals); Cipla Inc.; Lupin; Dr. Reddy's Laboratories Ltd.; Aurobindo Pharma; Sun Pharmaceutical Industries Ltd.; Novartis AG; Pfizer Inc.; Abbott; Sanofi; Bristol-Myers Squibb Company


Indication Insights

Based on indications, the global industry has been further bifurcated into pain and pyrexia (fever). The pain indication segment dominated the global industry in 2022 and accounted for the maximum share of more than 67.5% of the overall revenue. The high share of this segment was attributed to the effectiveness and rapid action of paracetamol being administered intravenously in pain management. A single dose of paracetamol given intravenously is effective in relieving pain for around 4 hours for about 37% of patients with acute post-operative pain. Moreover, paracetamol IV is effective and safe for the treatment of postoperative pain in both children and adults.

This, in turn, makes it more feasible to be used for a large patient pool. In addition, the product is considered a first-line treatment for acute pain and chronic pain as it is a non-addictive pain treatment. On the other hand, the pyrexia (fever) indication segment is projected to expand at the fastest growth rate during the forecast period. This can be attributed to the acceptance of paracetamol IV as the first line of treatment for fever and pain in pediatric patients. With the increasing pediatric population, the usage of paracetamol through infusion is also rising. However, the product is only used for short-term treatment, which, in turn, limits its adoption.

Application Insights

Based on applications, the global industry has been further categorized into surgical and non-surgical. The surgical application segment dominated the global industry in 2022and accounted for the maximum share of more than 64.45% of the overall revenue. The high share of this segment can be credited to the increased usage of paracetamol IV for the treatment of post-operative pain and quicker relief from fever. After surgery, most patients go through acute and mild pain, which, in turn, requires early treatment. With the increasing volumes of surgeries performed and the need to provide relief within a short duration of time, the adoption of paracetamol IV is projected to rise.

On the other hand, the non-surgical application segment is expected to register the fastest growth rate during the forecast period. The fastest growth of the non-surgical segment can be attributed to the increasing awareness among the population about the treatment of discomfort and fever-related symptoms. A wide range of paracetamol IV products is available in syringe form, which makes it easy to use and offers a quick effect. For instance, a liquid injectable form comprising acetaminophen, hydroxyethyl starch, and at least one osmolality agent is widely accepted as an infusion.

End-use Insights

Based on end-uses, the global industry has been further sub-segmented into hospitals, clinics, and others. The hospitals end-use segment dominated the overall industry in 2022. The segment accounted for the maximum share of more than 53.20% of the global revenue in the same year. It is projected to expand further at a significant growth rate during the forecast period maintaining its leading position. The dominance of this segment can be attributed to the increasing number of surgeries carried out in hospitals on account of the presence of qualified and specialized healthcare professionals.

The need for rapid relief from post-operative surgeries is further driving the growth of the segment. The clinics end-use segment is expected to account for the second-highest revenue share by 2030 on account of the increasing cases of short-term treatment of fever during urgent need to induce hypothermia. There is a high demand for treatments in clinics due to the easy access for remotely located patients. Moreover, the rising number of technological advancements and adoption of types of equipment in clinics is further spurring the growth of the segment.

Regional Insights

North America dominated the global sector in 2022 and accounted for the maximum share of more than 41.10% of the overall revenue. The dominance of the market is attributed to the popularity of paracetamol IV as it is one of the most frequently used medications with sales surpassing millions of doses every year. The formulation is highly used in hospitals and healthcare systems to treat patients with acute to mild pain. The use of the intravenous drug in emergency surgery, cohorts where the risk of morbidity can be reduced by adequately maintaining hemodynamics is further fueling the growth of the sector in this region.

Asia Pacific, on the other hand, is projected to grow at the fastest CAGR during the forecast period on account of the increasing prevalence of chronic diseases, rapid growth in the geriatric population, and the presence of key industry participants. Moreover, high product demand, due to lower costs associated with the drug and quick relief offered in postoperative pain, will drive the region’s growth over the coming years. For instance, according to the UNFPA, the older population in Asia is rising at an unprecedented rate, and it is expected to triple reaching 1.3 billion by 2050. Key players in the region include Cipla Inc., Sun Pharmaceutical Industries Ltd., and Lupin.

Some of the prominent players in the Paracetamol IV Market include:

  • Mallinckrodt (Mallinckrodt Pharmaceuticals)
  • Cipla Inc.
  • Lupin
  • Dr. Reddy's Laboratories Ltd.
  • Aurobindo Pharma
  • Sun Pharmaceutical Industries Ltd.
  • Novartis AG
  • Pfizer, Inc.
  • Abbott
  • Sanofi
  • Bristol-Myers Squibb Company

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Paracetamol IV market

  • Indication
    • Pain
    • Pyrexia (Fever)
  • Application
    • Surgical
    • Non-surgical
  • End-use
    • Hospitals
    • Clinics
    • Others

By Geography

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East & Africa (MEA)

Key Benefits for Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the global Paracetamol IV industry analysis from 2022 to 2030 to identify the prevailing Paracetamol IV industry opportunity.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the global Paracetamol IV industry segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global Paracetamol IV industry trends, key players, market segments, application areas, and market growth strategies.

Report Detail

  • Report Code:7609
  • No. of Pages:
  • Format:PDF/PPT/Excel

Proceed To Buy

USD 4500
USD 7900

Customization Offered

  • check-imgCross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers